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ABSTRACT 
 
 
Nearly 225 million cases of malaria were confirmed worldwide in 2009, causing 
781,000 deaths.  A majority of those deaths were among children in sub-Saharan Africa 
according to the World Health Organization. In this project the SIGLEC14/5 fusion gene 
was tested for its association with severe malaria, a complicated form of the disease, to 
help determine whether this copy number variant (CNV) plays a role in the genetic risk 
of severe malaria.  Matched malarial cases and controls from Tanzania were genotyped 
using conventional PCR methods, then the data was compiled.  The results indicate there 
is a possible association between this fusion gene and severe malaria. Further studies will 
need to be completed to confirm these assumptions.   
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BACKGROUND 
 
 
 
Malaria 
Nearly 225 million cases of malaria were confirmed worldwide in 2009, causing 
781,000 deaths.  A majority of those deaths were among children in Africa, resulting in a 
child‘s death every 45 seconds due to malaria (WHO, 2010).  Malaria is caused by the 
parasite Plasmodium falciparum, and its global distribution is shown in Figure 1.  Most 
of the cases (green) are concentrated in Africa, with significant numbers in Asia and 
South America. It is estimated that about 70% of malarial cases occur in Africa and about 
25% in South East Asia (Snow et al., 2005).  
 
 
Figure 1: Global Distribution of P. falciparum Endemicity.  (Snow et al., 2005). 
 
Of the hundreds of Plasmodium species, only four are known to cause human 
malaria. Plasmodium falciparum and Plasmodium vivax are the most common species. P. 
vivax is likely the most widespread malarial parasite due to the large populations within 
Asia, Latin America, and parts of Africa that it inhabits. The deadliest, however, is P. 
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falciparum causing most of the deaths in Africa south of the Sahara, as well as Papa New 
Guinea. Because this species multiplies quickly within the blood of its host, it can cause 
the onset of severe anemia. Cerebral malaria, hypoglycemia, respiratory distress and 
metabolic acidosis are also strictly associated with P. falciparum (CDC, 2010). 
Climate is a main factor for the transmission of malaria. Temperature, humidity, 
and rainfall all influence the survival and reproduction of the Anopheles mosquitoes that 
act as a vector for the spread of the parasite. The climate also affects the parasite‘s ability 
to complete its life cycle within both the vector and host. At temperatures below 20°C, P. 
falciparum is unable to complete its life cycle. Thus, malaria is typically transmitted in 
tropical and subtropical areas where the conditions are more favorable. Even within these 
areas, other variables are unfavorable for transmission such as higher altitudes, colder 
seasons, and deserts where there is a lack of water for which the mosquitoes breed.  The 
highest transmission of malaria occurs in regions around the equator where temperatures 
are much warmer (CDC, 2010).  
 
Life Cycle of P. falciparum 
When a female mosquito infected with P. falciparum takes a blood meal from a 
human host, sporozoites of the parasite are injected into that host. These sporozoites then 
infect the liver cells where they mature into schizonts that release merozoites when they 
rupture. The parasites undergo asexual reproduction in the erythrocytes after their initial 
replication in the liver cells. The merozoites then infect the red blood cells where they 
can either differentiate into gametocytes or continue the cycle of producing more 
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merozoites through the maturation of schizonts. These blood stage parasites are 
responsible for the appearance of the symptoms of malaria (CDC, 2010).  
Those merozoites that differentiate into gametocytes can be ingested by a female 
mosquito during a blood meal of an infected individual where the parasite reproduces 
during the sporogonic cycle forming zygotes. These zygotes are elongated and motile 
allowing them to invade the midgut wall of the mosquito. Here they develop into oocysts 
that mature and rupture to release sporozoites that are able to be injected into the host 
through the mosquito‘s salivary glands. This occurs 10-18 days after the gametocytes 
were ingested into the mosquito. This cycle enables the mosquito to pass the parasite on 
to multiple hosts causing widespread infection with malaria (CDC, 2010).   
 
Malaria Diagnosis and Treatment 
The symptoms of malaria can be mild or severe.  Severe malaria results from P. 
falciparum infection with delayed treatment (WHO, 2000). ―Severe malaria occurs when 
infections are complicated by serious organ failures or abnormalities in the patient's 
blood or metabolism (CDC, 2010).‖ Within the sub-Saharan Africa regions, there are 
three different manifestations of severe malaria which include cerebral malaria, acute 
respiratory distress, and severe malaria anemia which occur predominately in children 
(Bejon et al., 2007).  Typically, patients are misdiagnosed due to the common symptoms 
such as fever, diarrhea, headache, and body aches and pains. Patients lacking proper 
treatment tend to deteriorate quickly and experience a wide range of symptoms that may 
occur in combination with one another or individually (WHO, 2000). 
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Antimalarial drugs have been developed.  One of the most common drugs used to 
treat severe malaria is Quinine given intravenously via infusion pump. Other antimalarial 
drugs include Artemisinin, Artesunate, Artemether, Sulfadoxine–pyrimethamine, and 
Chloroquine (WHO, 2000).  During the mid-1900‘s Chloroquine was the preferred 
antimalarial drug, however due to its wide use resistance against the drug grew quickly 
primarily in Southeast Asia and South America. These regions have abandoned use of 
Chloroquine, but because of its affordability many countries in Africa still use it as their 
main defense against malaria. As resistance rates increase, this drug is becoming less of 
an option in all parts of the world (Djimde et al., 2001). Mefloquine is another 
antimalarial drug that is effective against falciparum malaria. This drug has particular 
importance because within 6 years of its release in 1984 significant resistance had been 
developed (Price et al., 2004).  Currently, artemisinin-based combination therapy (ACT) 
is the most effective treatment available (WHO, 2010). 
 
Malaria and Copy Number Variants 
Alterations of genomic DNA that span more than 1000 bases are known as 
structural genetic variation. The most prevalent type of structural genetic variation is 
copy number variants (CNVs).  CNVs have been known to cause genomic disorders 
including Williams–Beuren Syndrome and Charcot–Marie Tooth neuropathy Type 1A in 
which there are repeated CNVs at critical loci. Additionally, CNVs are present 
throughout the human genome among otherwise healthy individuals.  Keeping this in 
mind, research is currently being done to identify how CNVs may influence more 
common human diseases (Ionita-Laza, et al., 2009).  
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There are several features of CNVs that sustain their part in disease pathogenesis. 
First, the large size of CNVs disrupts sequences of functional DNA causing the cell to 
behave abnormally. Second, large quantities of CNVs seem to be concentrated in genes 
that help humans to adapt to changes in their environment, such as those genes that code 
for the immune system. Third, CNVs appear to be influenced by natural selective 
pressures indicating that their functions are significant. Lastly, ―53% of genes whose 
expression was influenced by CNVs had the corresponding CNV outside of the actual 
gene, suggesting that many CNVs could affect important regulatory sequences that are 
situated at a distance from the actual target gene (Ionita-Laza, et al., 2009).‖  Table 1 lists 
several diseases associated with CNVs. 
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Table 1: CNVs Associated with Complex Genetic Disease. 
CNV Complex Disease Associations 
CCL3L1 
HIV/AIDS susceptibility caused by decreased copies 
(Gonzalez, et al., 2005). Increased risk of rheumatoid 
arthritis due to increased copies (McKinney et al., 2007). 
FCGR3B 
Increased risk for lupus nephritis due to decreased copies 
(Aitman et al., 2006). 
UGTB17 
2-fold increased risk of osteoporosis associated with deletion 
(Yang et al., 2008). 
C4 
Increased risk of systemic lupus erythematous associated 
with deletion (Yang et al., 2007). 
DEFB4 
1.7-fold increased risk of psoriasis associated with >5 copies 
of beta-defensins (Hollox et al., 2007). 3-fold increased risk 
of Crohn disease associated with <4 copies (Fellermann et 
al., 2006). 
GSTM1 
Allergic responses, impaired lung function, and asthma 
associated with deletion (Brasch-Anderson et. al, 2004). 
LCE3B & 
LCE3C 
Psoriasis associated with multigene deletion of late cornified 
envelope genes (de Cid et al., 2009). 
 
With respect to malaria, in a population in West Africa it was shown that 
individuals having the HH131 genotype show increased susceptibility to severe malaria. 
A majority of these individuals were children less than five years old, an age group in 
which most cases of severe malaria occur. This genotype was caused by a copy number 
variant on the Fc receptor, FcγRIIa, in which a single nucleotide change alters a histidine 
(H) to an arginine (R) residue at position 131 and creates function change. This molecule 
provides a link between the humoral and cellular immune systems through its expression 
on the surface of lymphocytes and monocytes.  This association between CNVs and 
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severe malaria provides information about the immune system‘s capability of protecting 
individuals from severe malaria (Cooke et al., 2003).  
 
Siglecs 
Glycan-recognizing proteins within animals are classified into two groups which 
include lectins and sulfated glycosaminoglycan (SGAG)-binding proteins. I-type lectins 
are those proteins that mediate the identification of glycans through their 
immunoglobulin (Ig)-like domains. Siglecs (Sia-recognizing Ig-superfamily lectins) are a 
subfamily of these I-type lectins having sialic acid (Sia)-binding properties and amino-
terminal structural features.  One subgroup of the siglecs are those that have been 
conserved throughout evolution which include Siglecs-1, -2, and -4. The other is a 
CD33/Siglec-3-related subgroup which includes Siglecs-3 and -5–13 in primates that has 
been quickly evolving (Varki and Angata, 2006).  For the purposes of this project, the 
siglecs will be the main focus. 
Figure 2 depicts the main structural features of siglecs pertinent to their 
functions. The N-terminal ‗V-set‘ Ig domain of each siglec (A in the figure) binds ligands 
containing sialic acid. Each siglec also has anywhere from one to sixteen ‗C2-set‘ Ig 
domains (B in the figure) lengthen the distance between the ligand binding site and the 
membrane surface. Specificity for sialoside sequences on glycoprotein and glycolipid 
glycans present on either the same cell or neighboring cells by each siglec is variable. 
Immuno-receptor tyrosine-based inhibitory motif (ITIM) and ITIM-like motifs (C in the 
figure) are contained within the cytoplasmic domains of CD22 and most CD33-related 
siglecs.   
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Figure 2: Common Structural Features of Siglecs. The N-terminal ‗V-set‘ Ig domain 
(a) contains a conserved arginine residue that confers sialic-acid-binding ability. This 
domain is followed by a variable number (1–16) of ‗C2-set‘ Ig domains (b). In the 
cytosolic domain, most siglecs contain some combination of tyrosine motifs including 
ITIM, ITIM-like, Grb2-binding and Fyn kinase sites (c). Siglec-14, Siglec-15 and Siglec-
16 contain a positively charged residue in the transmembrane spanning region (d) that 
enables association with the ITAM-bearing adaptor protein DAP-12. It is speculated that 
these might have evolved to counteract ITIM-bearing siglecs. With 99% sequence 
identity in the two first N-terminal Ig domains, Siglecs-5 and Siglecs-14 are believed to 
be paired receptors (O‘Reilly and Paulson, 2009). 
 
The regulation of cell signaling is mediated via these Siglec motifs.  However, 
Siglec-14 to Siglec-16 and murine Siglec-H do not contain tyrosine motifs but rather 
have a transmembrane-spanning region that is positively charged. This positive charge 
allows for the adaptor protein DAP12 to associate with the charged region. DAP 12 
contains a cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM) which 
can transmit both positive and negative signals (O‘Reilly and Paulson, 2009). DAP12 is 
abundantly expressed in ―plasmacytoid dendritic cells, dendritic cells, neutrophils, 
basophils, eosinophils, monocytes, macrophages, microglial cells, and osteoclasts, as well 
as natural killer (NK) cells (Lanier, 2009).‖  Ligands encoded by either the host or by 
microbial pathogens have been shown to be recognized by DAP12-associated receptors. 
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This suggests that DAP12 plays an important role in initiating innate immune responses. 
Typically, when receptors employing ITAMs as modes of signaling, such as DAP12, are 
ligated they initiate cellular activation. Cytokines are then produced which causes 
degranulation in cytolytic effector cells (Lanier, 2009). 
Most CD33rSiglecs have formed a gene cluster located on the human 
chromosome 19 indicating that they have evolved substantially through gene 
duplications, deletions, and chimerism (Angata et al., 2006). Siglec-5 and Siglec-14 have 
extensive sequence similarity and are proposed to be paired inhibitory and activating 
receptors.  Via its arginine reside in the transmembrane domain, Siglec-14 can associate 
with the signaling adaptor molecule DAP12 which suggests that it functions as an 
activating receptor (Yamanaka et al., 2009). Siglec-5 has been found to be expressed on 
monocytes, granulocytes, plasmacytoid dendritic cells, monocyte-derived dendritic cells, 
and macrophages. Siglec-5 is also ―potentially involved in the negative regulation of 
innate immune responses (Angata et al., 2006).‖  In Yamanaka et al., a copy number 
variation was found between the region of the SIGLEC14 and SIGLEC5 genes fusing the 
two genes into what is called a SIGLEC14/5 fusion gene whose function is not fully 
understood.  In this project, the possible association of this SIGLEC14/5 fusion gene with 
severe malaria will be investigated.  
 
Previous Work 
Before beginning this project, the Bailey lab had identified Siglec-14 and Siglec-5 
genes as possible candidates for correlation with the contraction of severe malaria during 
an investigation of copy number variation via array comparative genomic hybridization 
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(CGH) of severe malaria cases and controls.  To validate the hybridization analysis, Dr. 
Reyburn provided the Bailey lab with 504 blood samples of severe malaria and 504 
village-matched controls, to be used in determining the effect that copy number 
variations may have on the contraction of severe malaria. For this project these samples 
were used to evaluate the possible association of the SIGLEC14/5 fusion gene with 
severe malaria.  
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PROJECT PURPOSE 
 
In this project, the SIGLEC14/5 fusion gene will be tested for its association with 
severe malaria.  This analysis will help determine whether CNVs play a role in the 
genetic risk in severe malaria. To do this, DNA was isolated from provided blood 
samples, and genotyped using conventional PCR methods. The number of cases having 
the 14/5 fusion gene compared with the number of controls having the fusion gene was 
then assessed.  Based on the significance of the results of this genotyping, the association 
of the fusion gene with severe malaria can determined.  Following this project, future 
studies will need to be completed to confirm the results. Possibly, this information can 
then be used to develop drug therapies that guard against severe malaria.   
 16 
METHODS 
 
PCR Design 
In the Yamanaka et al. (2009) study, the parameters for determining the genotype 
of individuals with regards to SIGLEC 14, SIGLEC 5, and SIGLEC 14/5 fusion 
genotypes were established.  Figure 3 depicts the primers and possible genotyping 
outcomes from this study. Wild type individuals have both SIGLEC 14 and SIGLEC 5 
genes intact, while null individuals have the SIGLEC 14/5 fusion gene, a deletion of a 
segment of DNA between SIGLEC 14 and SIGLEC 5 fusing the two genes. These genes 
were previously recognized by the Bailey lab as possible candidates for correlation with 
the contraction of severe malaria by a comparative genomic hybridization study.  
 
 
Figure 3: (B) Schematic Diagram for Genomic PCR of Siglec 14/5.  The primer pair 
5F + 5R specifically amplifies a part of the SIGLEC5 gene, and the primer pair 14F + 
14R a part of the SIGLEC14 gene. Genomic PCR with the primer pair 14F + 5R yields a 
∼1.6 kb product only when the SIGLEC14/5 fusion gene is present. This pair can 
theoretically amplify a ∼17 kb fragment from the wild-type allele as well, but failed to do 
so under the conditions used. (C) Expected gel electrophoresis pattern of PCR products 
for each genotype. (D) Genomic PCR results of the same set of individuals as in A. 
Donors 2, 4, and 5 are homozygotes for the null allele, as expected. (Yamanaka et al., 
2009) 
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Blood Samples 
Samples of whole blood were provided from collection sites in Tanga, Tanzania, 
in East Africa (Dr. Reyburn, KCMC Joint Malaria Program). Dr. Reyburn‘s study 
consisted of 504 hosptial malarial cases and 504 village controls. All cases and controls 
were matched based on age, ethnicity, and season by the collaborators at these sites. Dr. 
Reyburn is continually collecting samples providing potential new cases and controls to 
use in the future.  In addition, a site in Papua New Guinea (Dr. Mueller, PNG Institute of 
Medical Research) is currently completing a series of 400 cases and 400 controls of 
severe malaria that will provide us in the future with additional samples to continue 
further testing. Both studies have ensured that samples are truly taken from severe 
malaria patients by conducting blood cultures. Those cultures shown to contain bacterial 
infections associated with asymptomatic parasitemias are confirmed as severe malaria 
cases and deemed useable.  Ethical approval was received to conduct all of these human 
genetic studies.   The whole blood samples (biosafety level BSL-2) were handled by 
other personnel in the lab trained at BSL-2 levels. 
 
DNA Isolation 
DNA was isolated from whole blood samples by other personnel in the lab trained 
at BSL-2 biosafety levels using Qiagen‘s Blood & Cell Culture DNA Kit.   Purified DNA 
samples were no longer BSL-2 so could easily be handled for genotyping experiments. 
 
Siglec Genotyping 
In an attempt to validate and extend the information presented in the Yamanaka et 
al. (2009) study, a triplet set of primers were developed similar to their design, and were 
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used to genotype 362 samples.  However, those primers failed to show amplicons of the 
expected sizes, so a set of new primers were developed.  Primers used for the specific 
amplification of SIGLEC 14, SIGLEC 5, and SIGLEC 14/5 fusion genes were as follows: 
Sig F-24098a (5‘-CCTACCTATGCCGTTCCTGA-3‘), Sig R-25669a (5‘- 
AGCTGGACAAGCCTCACATC-3‘), Sig R-del25970a (5‘-
GGGGACCACATCTCTCTTGA-3‘).  These primers were designed using the Primer 3 
website and manufactured by Invitrogen. The primer triplets were used in amplification 
of genes homozygous for the SIGLEC 14/5 fusion product (Null/Null), homozygous for 
the SIGLEC 14 and SIGLEC 5 (WT/WT), or heterozygous for SIGLEC 14 and 5 and the 
SIGLEC 14/5 fusion product (WT/Null).  
Each PCR reaction tube contained the following for a total of 20 µL: 2 µL 
genomic DNA (~10 ng), 2 µL 10X PCR buffer, 0.4 µL dNTP solution (10 mM), 0.2 µL 
Platinum® Taq DNA Polymerase,  0.6 µL Magnesium Chloride (50 mM),  0.2 µL of 
each primer listed above, and 14.2 µL Sterile H2O. Thermal cycling parameters were as 
follows: 94°C for 2 minutes; (94°C for 20 seconds, 56°C for 30 seconds, 72°C for 100 
seconds) × 30 cycles; 72°C for 7 minutes; hold at 4°C. Completed PCR samples were 
then prepared to run on agarose gels by combining the following in each new tube: 3 µL 
Bromophenol blue dye and 8 µL PCR product. These were electrophoresed along with a 
standard DNA ladder. The agarose gel was prepared by combining the following: 0.6 g 
agarose, 50 mL 1X TAE Buffer, 1 uL ethidium bromide. Figure 4 depicts the new 
primers and possible genotyping outcomes.  
 
 19 
 
Figure 4: Siglec Primers Used in this Study and Genotyping Outcomes.  (A) The 
primer pair Sig F-24098a and Sig R-25669a amplifies a portion of the SIGLEC 14 gene, 
if present, and produces the lower PCR product band seen in (B) and (C).  The primer 
pair Sig F-24098a and Sig R-del125970a amplifies a portion of the SIGLEC 14/5 fusion 
gene, if present, and produces the upper PCR product band in (B) and (C). (B) Expected 
gel electrophoresis pattern of PCR products for each genotype. (C) Genomic PCR results 
of eight example individuals with their corresponding genotype. 
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RESULTS 
 
 
To determine whether the SIGLEC14/5 fusion gene is associated with severe 
malaria, 362 blood DNA samples were genotyped using conventional PCR. The results 
were compiled in the following tables displaying the genotype for each malarial case and 
matched controls. These tables also include statistical data including Chi-square values, 
p-values, Yates‘ Chi-square values, and Yates‘ p-values. Chi-square tests are used to 
detect group differences using frequency data. The Chi-square value and the degrees of 
freedom were used to calculate a p-value. Calculating the p-value can help determine if a 
random sampling from the data is likely to lead to a significant difference in the observed 
results. Typically, when the p-value is less than 0.05, the results are thought to be 
statistically significant.  
Table 2 shows the total set of 362 unmatched samples that were genotyped. The 
number of individuals with severe malaria and the WT/WT genotype was about the same 
as the number of individuals without severe malaria and the WT/WT genotype.  
Likewise, the number of individuals with severe malaria and the WT/Null genotype was 
about the same as the number of individuals without severe malaria and the WT/Null 
genotype.  Again, the number of individuals with severe malaria and the Null/Null 
genotype was about the same as the number of individuals without severe malaria and the 
Null/Null genotype. These results produced a p-value of 0.196 meaning that they are not 
statistically significant. From this data there does not seem to be any relationship between 
the SIGLEC14/5 fusion gene and resistance to severe malaria. However, keep in mind 
that the samples shown in Table 2 are unmatched, meaning that differences in age, 
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ethnicity, and season were not accounted for and could have caused the data to be 
skewed. 
 
 Table 2: Genotyping Results for 362 Unmatched Samples. 
Genotyping Results of Total Data Set  
(362 Unmatched Samples)  
Genotype  Case  Control  Total  
WT/WT  89  82  171  
WT/Null  69  85  154  
Null/Null  22  15  37  
Total  180  182  362  
 
Chi-square value:  3.262  
   
Degrees of Freedom:  2  
p-value:  0.196  
Yates' Chi-square:  2.623  
Yates' p-value:  0.269  
 
In the second set of results (Table 3) the statistical analysis was restricted to only 
include genotypic data from samples where data from both the severe malarial case and 
the matched control were available. In this case, for the WT/WT Siglec genotype, the 
number of individuals with severe malaria is approximately equal to the number of 
control samples. This is also the case for the WT/Null genotype.  However, for the 
Null/Null genotype, the number of severe malarial cases is more than double the control 
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cases. These results produced a p-value of 0.031 meaning that they are statistically 
significant. From this data it seems that there is likely a relationship between the 
SIGLEC14/5 fusion gene and increased susceptibility to severe malaria. 
Table 3: Genotyping Results for 228 Matched Samples. 
Genotyping Results of All Matched Cases and Controls 
(228 Matched Samples)  
Genotype  Case  Control  Total  
WT/WT  54  57  111  
WT/Null  42  51  93  
Null/Null  18  6  24  
Total  114  114  228  
 
Chi-square value:  6.952  
   
Degrees of Freedom:  2  
p-value:  0.0310  
Yates' Chi-square:  5.766  
Yates' p-value:  0.0560  
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DISCUSSION 
 
 
From this study it was determined that data from the entire 362 unmatched sample 
set (Table 2) produced p-values well above 0.05, indicating that no association appeared 
to exist between severe malaria and the Siglec 15/5 fusion genotype in the total set of 
unmatched samples, but when the data set was restricted to a subset of 228 matched 
samples (Table 3), the resulting p-values suggest that an association may, in fact, be 
valid. This indicates that the fusion genotype may correlate with an increased 
susceptibility to severe malaria. 
During this project few problems were encountered, but the few problems that did 
exist were time consuming to solve. First, the primers used in the earlier Yamanaka study 
proved to be unsuccessful in producing any amplicon product for the blood DNA samples 
that were used in this project. So a new set of primers had to be developed and tested for 
productivity. This set of primers eliminated the need for both a primer set for SIGLEC14 
and another primer set for SIGLEC5 for which multiple PCR reactions would have been 
required. Instead, the new triplet set of primers provided product for each genotype 
within a single PCR reaction. Second, the parameters of the PCR reaction had to be 
adjusted to produce adequate readings of the results. The time for initial denaturation had 
to be extended and the annealing temperature was adjusted slightly. For the denaturation, 
annealing, and extension period, the time had to be increased significantly while 
adjusting the temperature slightly. The number of cycles that this period completed was 
increased in an attempt to produce more product. The final extension time had to be 
decreased as well. Finally, the type of Taq polymerase was changed from that found in 
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the Bio-Rad iProof
TM
 High-Fidelity PCR Kit to the Platinum® Taq DNA Polymerase 
provided by Invitrogen.  
Copy number variations within the human genome have previously been found to 
be associated with immunity and infectious disease. In this project it is believed that the 
SIGLEC14/5 fusion gene may provide individuals with resistance to severe malaria 
similar to the CNV found on FcγRIIa that caused increased susceptibility to severe 
malaria in the Cooke study. Although not much is known about the SIGLEC14/5 fusion 
gene and its functions, this project presents information from which assumptions can be 
made.  Perhaps the normal function of the Siglec-14 and Siglec-5 genes is to associate 
with the adaptor protein DAP12 causing activation of natural killer cells that can then 
destroy invading P. falciparum parasites. This fusion gene may disrupt this function 
leaving cells vulnerable to invasion.  
This project was successful in determining that there is a possible association 
between the SIGLEC14/5 fusion gene and severe malaria. However, continued 
genotyping of the samples provided by Dr. Reyburn‘s study would provide a larger 
sample size making for more reliable data.  Determining the tribe within Tanzania from 
which each sample was taken would be helpful in determining if certain data sets should 
be excluded from the study.  This data might also be useful in tracking the genetic lineage 
of this gene throughout that region. Given that the fusion gene proves to be strongly 
associated to severe malaria, future studies into the possible development of drug 
therapies could be a viable option to help combat severe malaria. 
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